GH
Guardant HealthยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
GH Profile
Guardant Health, Inc.
A leading precision oncology company that provides non-invasive cancer testing and analytics
Biological Technology
--
10/04/2018
NASDAQ Stock Exchange
1,999
12-31
Common stock
3100 Hanover Street, Palo Alto, California, 94304
--
Guardant Health, Inc., was incorporated in Delaware in December 2011. The company is a leading precision oncology company dedicated to helping the world conquer cancer through the use of its proprietary blood tests, extensive datasets and advanced analysis. Guardant Health, Inc., believes that the key to conquering cancer is unprecedented access to its molecular information at all stages of the disease, which they intend to achieve through routine blood draws or liquid biopsies. Guardant Health Guardant Health Oncology Platform aims to leverage its capabilities in technology, clinical development, regulation and reimbursement to drive commercial applications, improve patient clinical outcomes and reduce healthcare costs. In order to achieve their goal of managing cancer at all stages of the disease, the company has launched their liquid biopsy tests, Guardant 360 and Guardant OMNI, for the treatment of advanced cancer, to power the company's program of recurrence and early detection testing, LUNAR-1 and LUNAR-2, respectively.
